JP2011529917A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529917A5
JP2011529917A5 JP2011521360A JP2011521360A JP2011529917A5 JP 2011529917 A5 JP2011529917 A5 JP 2011529917A5 JP 2011521360 A JP2011521360 A JP 2011521360A JP 2011521360 A JP2011521360 A JP 2011521360A JP 2011529917 A5 JP2011529917 A5 JP 2011529917A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
alkynyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011521360A
Other languages
English (en)
Japanese (ja)
Other versions
JP5431476B2 (ja
JP2011529917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/052439 external-priority patent/WO2010014921A2/en
Publication of JP2011529917A publication Critical patent/JP2011529917A/ja
Publication of JP2011529917A5 publication Critical patent/JP2011529917A5/ja
Application granted granted Critical
Publication of JP5431476B2 publication Critical patent/JP5431476B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011521360A 2008-08-01 2009-07-31 A3アデノシン受容体アンタゴニストおよびa3アデノシン受容体部分アゴニスト Expired - Fee Related JP5431476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8558808P 2008-08-01 2008-08-01
US61/085,588 2008-08-01
PCT/US2009/052439 WO2010014921A2 (en) 2008-08-01 2009-07-31 A3 adenosine receptor antagonists and partial agonists

Publications (3)

Publication Number Publication Date
JP2011529917A JP2011529917A (ja) 2011-12-15
JP2011529917A5 true JP2011529917A5 (cg-RX-API-DMAC7.html) 2012-07-12
JP5431476B2 JP5431476B2 (ja) 2014-03-05

Family

ID=41111356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521360A Expired - Fee Related JP5431476B2 (ja) 2008-08-01 2009-07-31 A3アデノシン受容体アンタゴニストおよびa3アデノシン受容体部分アゴニスト

Country Status (6)

Country Link
US (1) US8796291B2 (cg-RX-API-DMAC7.html)
EP (1) EP2331542B1 (cg-RX-API-DMAC7.html)
JP (1) JP5431476B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009276411B2 (cg-RX-API-DMAC7.html)
CA (1) CA2732320C (cg-RX-API-DMAC7.html)
WO (1) WO2010014921A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
US8916570B2 (en) * 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2011035941A1 (en) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2598480B1 (en) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2750671A2 (en) * 2011-05-19 2014-07-09 Oryzon Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
WO2012156531A2 (en) * 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP2013256491A (ja) * 2012-05-14 2013-12-26 Kyoto Univ 不安定プラークへの選択的集積性に優れる化合物
WO2015080940A1 (en) 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
CN109310695B (zh) 2016-04-21 2022-04-01 阿斯特罗赛特制药公司 治疗神经和心血管病况的化合物和方法
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
US11839615B2 (en) 2018-02-09 2023-12-12 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
EP3856741A4 (en) 2018-09-26 2022-06-22 Astrocyte Pharmaceuticals, Inc. POLYMORPHOUS COMPOUNDS AND USES THEREOF
US12397010B2 (en) 2019-02-15 2025-08-26 Saint Louis University Treatment of chronic headaches
WO2022040241A1 (en) 2020-08-17 2022-02-24 Biointervene, Inc. A3 adenosine receptor agonists for use in medicine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
US5840728A (en) * 1996-08-07 1998-11-24 United States Of America As Represented By The Department Of Health And Human Services Conformationally locked nucleoside analogs as antiherpetic agents
CN1265572A (zh) * 1997-04-30 2000-09-06 莱兰斯坦福初级大学评议会 活体内造影细胞死亡的方法
WO1998050047A1 (en) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
DE69837095T2 (de) * 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
EP1096975B1 (en) * 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
ATE336492T1 (de) * 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20030143282A1 (en) * 2002-01-28 2003-07-31 Pnina Fishman Adenosine A3 receptor agonist
US20060100168A1 (en) * 2002-09-30 2006-05-11 The Trustee Of Boston University Method of treating cancer using adenosine and its analogs
KR20070050484A (ko) * 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 A1 및 a3 아데노신 수용체 아고니스트로서의 퓨린 유도체
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
US20090192077A1 (en) 2005-04-15 2009-07-30 Shizuko Sei North-2'deoxy -methanocarbathymidines as antiviral agents for treatment of kaposi's sarcoma-associated herpes virus
US7381714B2 (en) 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US20090221523A1 (en) 2005-05-25 2009-09-03 Tseng Christopher K North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses
WO2007002139A2 (en) 2005-06-22 2007-01-04 The Trustees Of The University Of Pennsylvania Neuroprotection of retinal ganglion cells
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007043054A1 (en) 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
JP5339916B2 (ja) 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるa3アデノシン受容体アゴニストの使用
EP1798233A1 (en) 2005-12-19 2007-06-20 Faust Pharmaceuticals Pyrrolo[1,2-a]quinoxaline derivatives as Adenosine A3 receptor modulators and uses thereof
AU2006336834B2 (en) 2006-01-27 2009-12-10 Can-Fite Biopharma Ltd. Adenosine A3 receptor agonists for the treatment of dry eye disorders
EP2001881A2 (en) 2006-03-07 2008-12-17 Endacea, Inc. Compositions and methods for treating respiratory disorders
GB0607944D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
ES2526713T3 (es) * 2006-05-23 2015-01-14 University Of Connecticut Derivados de N-metanocarba para tratar enfermedades cardiacas
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
US20100062994A1 (en) 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008058238A2 (en) 2006-11-08 2008-05-15 Thomas Jefferson University Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
WO2008055711A2 (en) 2006-11-09 2008-05-15 Centre De Recherche Public De La Sante Use of an adenosine antagonist
WO2008056361A1 (en) 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
GB0625100D0 (en) 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US8916570B2 (en) * 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) * 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
WO2010014921A2 (en) 2008-08-01 2010-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) * 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
EP2507241A1 (en) * 2009-12-02 2012-10-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2012145098A1 (en) * 2011-04-21 2012-10-26 Saint Louis University Use of adenosine a3 receptor agonists for treatment of neuropathic pain

Similar Documents

Publication Publication Date Title
JP2022050538A (ja) プロスタサイクリン(pgi2)受容体に関連する障害の処置に有用なpgi2受容体の調節因子
KR102441242B1 (ko) 2-(2,4-디플루오로페닐)-1,1-디플루오로-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2020502115A5 (cg-RX-API-DMAC7.html)
RU2013114351A (ru) Пестицидные композиции
RU2006120441A (ru) Комбинация действующих веществ с инсектицидными свойствами
JP2011529964A5 (cg-RX-API-DMAC7.html)
WO2021076688A1 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
BR112013003245B1 (pt) Derivados de heteroarilpiperidina e -piperazina como fungicidas e composição para controlar fungos fitopatogênicos prejudiciais os compreendendo e uso dos mesmos, método para controlar fungos fitopatogênicos prejudiciais, bem como processo para produzir composições para controlar fungos fitopatogênicos prejudiciais
JP2009519243A5 (cg-RX-API-DMAC7.html)
JP2006505543A5 (cg-RX-API-DMAC7.html)
RU2010107171A (ru) Фунгицидные n-циклоалкилбензилтиокарбоксамиды или n-циклоалкилбензил-n, -замещенные амидиновые производные
HUP0105098A2 (hu) Fungicid hatású N2-fenil-amidin származékok, intermedierjeik és alkalmazásuk
CA2766199A1 (en) Thiazolylpiperidine derivates as fungicides
JP2019535723A5 (cg-RX-API-DMAC7.html)
RU2011136250A (ru) Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство
JP2007505931A5 (cg-RX-API-DMAC7.html)
JP2020502052A5 (cg-RX-API-DMAC7.html)
CA2722734A1 (en) 3,4-substituted piperidine derivatives as renin inhibitors
JP2019532067A5 (cg-RX-API-DMAC7.html)
WO2019048988A1 (en) Novel fungidal heterocyclic compounds
JP2010534246A5 (cg-RX-API-DMAC7.html)
JP2005511602A5 (cg-RX-API-DMAC7.html)
JP4464140B2 (ja) 殺菌剤として有用なケイ素化フェニルアミド誘導体